← Back to headlines
New Drug Doubles Survival for Pancreatic Cancer Patients
A new targeted therapy against RAS proteins has shown to double the survival rate for pancreatic cancer patients, marking a significant breakthrough in the treatment of the disease. RAS proteins are responsible for over 90% of pancreatic cancer cases.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
